Key result
Diabetes linked to ~37% higher MACE risk vs non-diabetics following bifurcation PCI.
Why the study?
The impact of diabetes mellitus in complex coronary lesions treated with PCI, which themselves have an increased incidence of adverse events, remains unclear.
Does diabetes mellitus worsen outcomes in patients undergoing percutaneous coronary intervention for coronary bifurcation lesions?
Cohort (n=5,537)
Yes
Does diabetes mellitus worsen outcomes in patients undergoing percutaneous coronary intervention for coronary bifurcation lesions?
Diabetes mellitus is an independent predictor of worse long-term outcomes, including MACE, all-cause death, TLR, and stent thrombosis, in patients undergoing PCI for coronary bifurcation lesions.
DM associated with higher adjusted MACE after bifurcation PCI; extends prior risk data but leaves optimal mitigation strategies open.
BACKGROUND: It is still unclear the impact of diabetes mellitus (DM) in complex coronary lesions treated with percutaneous coronary intervention (PCI) which themselves are at increased incidence of adverse events. METHODS: BIFURCAT registry encompassed patients treated with PCI for coronary bifurcation lesion from the COBIS III and the RAIN registry. The primary endpoint was the occurrence of major cardiovascular adverse event (MACE), a composite and mutual exclusive of all-cause death or myocardial infarction (MI) or target-lesion revascularization (TLR). A total of 5537 patients were included in the analysis and 1834 (33%) suffered from DM. RESULTS: After a median follow-up of 21 months, diabetic patients had a higher incidence of MACE (17% vs. 9%, p < 0.001), all-cause mortality (9% vs. 4%, p < 0.001), TLR (5% vs. 3%, p = 0.001), MI (4% vs. 2%, p < 0.001), and stent thrombosis (ST) (2% vs. 1%, p = 0.007). After multivariate analysis, diabetes remained significantly associated with MACE (hazard ratio [HR]: 1.37; confidence interval [CI]: 1.13-1.65; p = 0.001), all-cause death (HR: 1.65; 95% CI: 1.24-2.19, p = 0.001), TLR (HR: 1.45; CI: 1.03-2.04; p = 0.031) and ST (HR: 1.73, CI: 1.04-2.88; p = 0.036), but not with MI (HR: 1.34; CI: 0.93-1.92; p = 0.11). Among diabetics, chronic kidney disease (HR: 2.99; CI: 2.21-4.04), baseline left ventricular ejection fraction (HR: 0.98; CI: 0.97-0.99), femoral access (HR: 1.62; CI: 1.23-2.15), left main coronary artery (HR: 1.44; CI: 1.06-1.94), main branch diameter (HR: 0.79; CI: 0.66-0.94) and final kissing balloon (HR: 0.70; CI: 0.52-0.93) were independent predictors of MACE at follow-up. CONCLUSIONS: Patients with DM treated with PCI for coronary bifurcations have a worse prognosis due to higher incidence of MACE, all-cause mortality, TLR and ST compared to the non-diabetics.
No takes yet. Share an insight, caveat, or question.
Bruno et al. (2023) conducted a cohort in Coronary bifurcation lesion (n=5,537). Diabetes mellitus vs. Non-diabetics was evaluated on Major cardiovascular adverse event (MACE), a composite of all-cause death, myocardial infarction (MI), or target-lesion revascularization (TLR) (HR 1.37, 95% CI 1.13-1.65, p=0.001). Diabetes mellitus was associated with a higher risk of MACE compared to non-diabetics following PCI for coronary bifurcation lesions (17% vs 9%; adjusted HR 1.37; 95% CI 1.13-1.65; p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: